TNXP - Tonix Pharmaceuticals Holding Corp Stock Price, Fair Value and News

$17.78+2.26 (+14.56%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TNXP Price Action

Last 7 days

17.9%

Last 30 days

-5.2%

Last 90 days

-32.4%

Trailing 12 Months

-3.9%

TNXP RSI Chart

TNXP Valuation

Market Cap

209.4M

Price/Earnings (Trailing)

-2.11

Price/Sales (Trailing)

76.45

Price/Free Cashflow

-2.74

TNXP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TNXP Fundamentals

TNXP Revenue

Revenue (TTM)

2.6M

Rev. Growth (Yr)

16.58%

Rev. Growth (Qtr)

217.57%

TNXP Earnings

Earnings (TTM)

-99.2M

Earnings Growth (Yr)

-125.22%

Earnings Growth (Qtr)

-13.22%

TNXP Profitability

Operating Margin

-160.79%

Return on Equity

-42.93%

Return on Assets

-39.3%

Free Cashflow Yield

-36.45%

TNXP Investor Care

Buy Backs (1Y)

92.10%

Diluted EPS (TTM)

1.3K

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	10.1M	12.5M	11.3M	2.6M
2023	0	0	0	7.8M
2011	0	0	0	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, develops therapeutics and vaccines to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed to treat autoimmune conditions. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; and TNX-102 SL, a CNS product candidate to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a recombinant protein enzyme to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

CEO	Dr. Seth Lederman M.D.
WEBSITE	tonixpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	117

Tonix Pharmaceuticals Holding Corp Frequently Asked Questions

What is the ticker symbol for Tonix Pharmaceuticals Holding Corp? What does TNXP stand for in stocks?

TNXP is the stock ticker symbol of Tonix Pharmaceuticals Holding Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tonix Pharmaceuticals Holding Corp (TNXP)?

As of Wed Dec 03 2025, market cap of Tonix Pharmaceuticals Holding Corp is 209.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNXP stock?

You can check TNXP's fair value in chart for subscribers.

Is Tonix Pharmaceuticals Holding Corp a good stock to buy?

The fair value guage provides a quick view whether TNXP is over valued or under valued. Whether Tonix Pharmaceuticals Holding Corp is cheap or expensive depends on the assumptions which impact Tonix Pharmaceuticals Holding Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNXP.

What is Tonix Pharmaceuticals Holding Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, TNXP's PE ratio (Price to Earnings) is -2.11 and Price to Sales (PS) ratio is 76.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNXP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tonix Pharmaceuticals Holding Corp's stock?

In the past 10 years, Tonix Pharmaceuticals Holding Corp has provided -0.789 (multiply by 100 for percentage) rate of return.